This paper describes a new procedure for the enantioselective synthesis of the important anticonvulsant drug Pregabalin, which shows biological properties as the (S) enantiomer only. The key step of the synthetic sequence is the Michael addition reaction of Meldrum's acid to a nitroalkene mediated by a quinidine derived thiourea. A variety of novel catalysts bearing different groups at the thiourea moiety were synthesized and tested. The most successful catalyst that incorporates a trityl substituent provided up to 75 % ee of (S)-4. The conjugate addition reaction was carried out on a
Introduction
Pregabalin is the international non-proprietary name for (3S)-3-(aminomethyl)-5-methylhexanoic acid (1) (Figure 1 ). It belongs to the group of 3-substituted analogues of the inhibitory neurotransmitter γ-aminobutyric acid (GABA), such as gabapentin and baclofen. Discovered by Silverman et al. [1] in 1991, Pregabalin is an anticonvulsant drug used to treat epilepsy and neurophatic pain marketed by Pfizer under the brand name Lyrica ® . It is considered as one of the drugs of the future due to its high and broad therapeutic activity and reaches blockbuster status (1 billion $ annual sales or more); thus, the development of simple efficient synthetic processes has become an important research goal for medicinal and organic chemists. Because only the (S) enantiomer exhibits the desired pharmacological activity [2] enantioselective syntheses are in demand. The initial industrial preparation of Pregabalin involved a resolution of rac-1 with (+)-(S)-mandelic acid. [3] The process provided 1 in low yields accompanied by high manufacturing costs. Due to the need of preparing compounds in enantiopure form, several asymmetric syntheses have been reported. [4] To mention some selected examples, Yuen et al.
[4a] prepared both enantiomers of Pregabalin using Evans' chiral oxazolidinone alkylation chemistry. Brenner and Seebach [4b] prepared (R)-N-Boc Pregabalin methyl ester by 1,4-addition of a titanium enolate generated from an N-acetyloxazolidinone to the corresponding (isobutyl)(nitro)alkene. Catalytic methods for the enantiomerical preparation of Pregabalin have also been developed. The Pfizer manufacturing process [4c] is based on asymmetric hydrogenation of a prochiral substituted 3-cyanohexenoic acid by using Chirotech's commercially available rhodium catalyst. Sammins and Jacobsen [4e] have described a highly enantioselective route to 1 through conjugate addition of cyanide to α,β-unsaturated imide by salen Al catalysis. Shibasaki's group [4g] developed a catalytic enantioselective conjugate addition reaction of cyanide to α,β-unsaturated N-acylpyrrole mediated by a chiral gadolinium catalyst. On the other hand, recently Armstrong et al. [4h] described the synthesis of enantiopure Pregabalin through conjugate addition of cyanide to a chiral α,β-unsaturated isobutyloxazolidinone. Poe et al. [4j] have also synthesized 1 by a one-pot reaction between isovaleraldehyde, nitromethane and dimethyl malonate promoted by two microencapsulated catalysts. Pregabalin has also been obtained by catalytic enantioselective conjugate addition of nitroalkanes to α,β-unsaturated aldehydes using diphenylprolinol silyl ether as organocatalyst.
[4m] Moreover, very recently 1 has been industrially produced by chemoenzymatic methods.
[4o]
Our synthetic strategy towards enantiopure Pregabalin is depicted in Scheme 1. We envisaged that the target compound could be obtained from chiral nitroalkane 4 through reduction of the nitro group and simultaneous removal of the acetonide followed by decarboxylation. In turn, the nitro compound 4 could be accessible by two possible routes, A and B, that rely on enantioselective conjugate addition reactions. Route A implies unsaturated Meldrum's acid derived acceptor 3 as the electrophile and nitromethane as the nucleophile, whereas route B is based on the use of nitro olefin 3 as the Michael acceptor and Meldrum's acid as the nucleophile. Our choice of Meldrum's acid as the malonate surrogate was based on the expected ease of the operation for the release of the eventual acid under mild, slightly acidic conditions. For the catalytic asymmetric conjugate addition [5] step we decided to employ thioureas derived from cinchona alkaloids [6] as organocatalysts for both routes. These systems, bearing a tertiary amine and a thiourea moiety, offer a dual activation of the substrate and reagent. In previous work, the enantioselective conjugate addition of nitroalkanes to enones by using cinchona alkaloid based thioureas has been described by Soós' and Ye's groups.
[6b,6p,6q,7] Additionally, asymmetric Michael addition reactions of malonate esters to nitro olefins catalyzed by epicinchona alkaloid derivatives have recently been reported.
[6c,6d,6o] We decided to synthesize the previously reported 9-amino-(9-deoxy-)epiquinidine-derived thiourea catalyst 8 and novel catalysts 9-17, which incorporate different substitution pattern at the thiourea moiety. This family of organocatalysts were tested under Michael addition reactions for both routes to nitroalkane 4. In this paper, we report the preparation of the Michael acceptors, catalysts and our results concerning the enantioselective conjugate addition reactions for routes A and B. The resulting optically active nitro compound 4 may then be transformed to Pregabalin (1) .
Synthesis of the Substrates and Organocatalysts
The starting electron-poor alkenes 2 and 3 were accessed from isovaleraldehyde (Scheme 2). Michael acceptor 2 was obtained cleanly by Knoevenagel condensation in water from both commercially available Meldrum's acid and isovaleraldehyde [8] by carrying out the reaction in a closed vessel at 75°C for 2 h. On the other hand, nitro olefin 3 was synthesized in good yields as the (E) isomer, by a Henry reaction between nitromethane and isovaleraldehyde, followed by dehydration of the intermediate nitro alcohol with trifluoroacetic anhydride and triethylamine. [9] Scheme 2. Synthesis of Michael acceptors 2 and 3.
Preparation of the thiourea organocatalysts started by obtaining a range of isothiocyanates, which serve as thiourea functionality. 3,5-Bis(trifluoromethyl)phenyl isothiocyanate (18) and trityl isothiocyanate (19) were purchased from commercial sources. Compounds 20-23 were obtained in moderate to excellent yields (Scheme 3) from the corresponding chiral or achiral primary amines by reaction with carbon disulfide and DCC. [10] The synthesis of compound 24 was accomplished by nucleophilic substitution in acetone between potassium thiocyanate [11] and 9-bromo-9-phenylfluorene. In this case, a separable mixture of the corresponding isothiocyanate and thiocyanate was obtained. Isothiocyanate 27 was prepared from commercially available 1-bromonaphthalene by a Grignard reaction with ethyl formate [12] to alcohol 26 which was converted to isothiocya- nate 27 by an oxalic acid catalyzed reaction with sodium thiocyanate. [13] Isothiocyanate 29 was prepared on a multigram scale by conversion of 1-bromo-3,5-dimethylbenzene to the aryllithium species and its reaction with commercially available methyl 3,5-dimethylbenzoate to give the corresponding alcohol 28 in excellent yield. [14] Similarly, alcohol 28 was converted to isothiocyanate 29 following oxalic acid catalyzed nucleophilic substitution with potassium thiocyanate (Scheme 4). The synthesis of thiourea organocatalysts can be conducted according to two complementary procedures. First, condensation of the free amine derived from quinidine with isothiocyanates provided thioureas 8-15 in good yields (Scheme 5). The second method is based on the treatment of the chiral isothiocyanate 23 obtained from amine 7 with primary amines. This procedure gave thioureas 16 and 17 (Scheme 6). As a representative example, the structure of catalyst 12 was confirmed by X-ray crystallography (Figure 2 ). [15] Figure 2. X-ray structure for catalyst 12.
Screening of the Catalysts
We started our investigations by testing these organocatalysts to evaluate their ability to promote the conjugate addition of nitromethane to compound 2. Initially, we selected catalyst 8 [6b] that incorporates a 3,5-bis(trifluoromethyl)-phenylthiourea. After 4 d at room temperature, the reaction was complete but gave a very modest enantioselectivity (21.4 % ee, Table 1 , Entry 1) affording the nitro compound 4 with the desired stereochemistry.
Performing the reaction with tert-butylthiourea 9 the enantiocontrol was much lower (4.5 % ee, Table 2 , Entry 6). Catalyst 14 was tested to analyze the influence of substitution in the aromatic rings of the trityl group. Unfortunately, the enantioselectivity decreased to 55.5 % (Table 2, Entry 7). We then turned our attention to organocatalysts 15 and 16, which incorporate a chiral naphthylethyl moiety. They showed small matched/ mismatched effects providing Michael adduct 4 in high yields and in 52.6 and 57.2 % ee, respectively (Entries 8 and 9). Finally, thiourea 17 gave full conversion but lower enantioselectivity (Entry 10).
Enantioselective Synthesis of Pregabalin
The high level of asymmetric induction and efficiency exhibited by thiourea 13 to provide nitro compound 4 according to route B prompted us to choose it as the organocatalyst for the enantioselective synthesis of Pregabalin. The sequence of the present enantioselective synthesis of (3S)-3-(aminomethyl)-5-methylhexanoic acid (1) is outlined in Scheme 7. Reaction of nitroalkene 3 (100 mol-%, 33.6 mmol), Meldrum's acid (100 mol-%, 33.6 mmol), and organocatalyst 13 (10 mol-%, 3.36 mmol) in DCM (1 m) at room temp. for 23 h provided 4 in 84 % yield and in 74.6 % ee after purification by column chromatography. Moreover, catalyst 13 was recovered in good yield (55 %) after column chromatography and was reused. The recovered catalyst was also effective in the second reaction, showing the same activity and selectivity. The chemical yield of the second run was 82 % and the ee again 74.6 %. Then, hydrogenation of 3-(nitromethyl)alkane 4 in the presence of Raney-Ni as catalyst in acetic acid at room temp. and atmospheric pres- sure afforded amino diacid 5, which after treatment with 6 n HCl yielded hydrochloride 1. Enantioenrichment by crystallization [16] of the free amino acid from 2-propanol/ water furnished 1 as a white crystalline solid with 80 % ee. 
Origin of the Enantioselectivity
The nitro group is well known to interact with thiourea through hydrogen bonding. Thioureas have two hydrogen bonds to bind the H bond acceptor. These interactions increase the electrophilicity of the electron-deficient alkene bearing the nitro group. As seen from the X-ray structure of 12 ( Figure 3 ), in the solid state this catalyst exists as a trans/cis rotamer (based on the HNCS angle) which apparently is less accessible for hydrogen bonding than the trans/trans rotamer. Tsogoeva et al. [17] have also reported the trans/cis conformer in the solid state of a chiral (methylpyridyl)thiourea displaying intramolecular hydrogen bonding between one of the thiourea NH groups and the basic nitrogen atom of the pyridyl group as well as an intermolecular hydrogen bond from the H atom of the thiourea NH group to the sulfur atom of a second molecule leading to a dimer. They claim that these interactions do not allow its imine substrate to be placed in a bridging mode between the two thiourea hydrogen atoms. According to them, this may be the reason of the very poor levels of enantioselectivity (6 % ee) observed in the Strecker synthesis by employing this catalyst.
In our case, our catalysts provide very good enantioselectivities (up to 75 % ee), even though we observed the same disposition. In solution, thioureas typically are present as a mixture of trans/trans and trans/cis conformers ( Figure 4) . [18] In the first conformation the two oxygen atoms of the nitroalkene would form two hydrogen bonds with both H atoms of the thiourea at the same time, whereas the trans/cis conformer can only provide one point of attachment, thus giving a less restricted substrate binding and weakened enantiocontrol. In the Michael addition of 1,3-dicarbonyl compounds to nitro olefins catalyzed by bifunctional thioureas Takemoto et al. [19] suggested that the active monomeric organocatalyst binds the nitroalkene through double hydrogen bonding. In our case of Meldrum's acid addition to nitro olefin 3 we propose a transition-state model similar to that by Takemoto, which would imply activation of the Michael acceptor 3 through double NH hydrogen bonding. The quinuclidine ring is orientated towards the same direction where the two NH groups are and placed on the same face with the trityl group, but both away from each other to avoid steric interaction. On the basis of the product configuration, delivery of the enolate from the top face to the s-cis nitroalkene would provide (S)-4 ( Figure 5 ). In agreement with this interpretation, the decrease in ee of product 4 with catalyst 14 could be attributed to steric hindrance between the methyl substituents at the meta position of the trityl group and the isopropyl moiety of the nitroalkene 3. This repulsion would shift the nitroalkene to the s-trans conformation, in which delivery of the enolate from the top face would lead to (R)-4. 
Conclusions
We have developed a simple short procedure for preparing multigram quantities of the antiepileptic drug Pregabalin by organocatalytic conjugate addition reaction of Meldrum's acid to nitroalkene 3. We have synthesized and tested a family of novel catalysts to promote the above reaction. The best enantioselectivity was obtained with catalyst 13, which incorporates a trityl substituent in the thiourea moiety and can be recycled. The key intermediate nitro compound 4 was obtained in high chemical yield after purification by column chromatography and up to 75 % ee of the (S) enantiomer. Moreover, the overall yield for the process starting from 3 is 59 %, and enantioenrichment by crystallization of the free amino acid provides almost enantiopure Pregabalin.
Experimental Section
General Considerations: All moisture-sensitive reactions were performed under argon in flame-dried, round-bottomed flasks fitted with rubber septa and/or glass stoppers. For reactions run at low temperatures, flasks were flushed with argon, and double septa to minimize the introduction of adventitious water. Stainless steel syringes were used to transfer air-or moisture-sensitive liquids.
Materials: Unless otherwise indicated, reagents were used as purchased from suppliers. Solvents were dried prior to use according to standard procedures. Toluene was distilled from sodium, tetrahydrofuran from sodium/benzophenone ketyl, dichloromethane, triethylamine and diethylamine from calcium hydride (CaH 2 ). All reactions were performed under a positive pressure of argon when necessary. Thin layer chromatography was done on SiO 2 (silica gel 60 F 254 , Merck, coated aluminium plates), and the spots were located with UV light (254 nm), with aqueous potassium permanganate and ninhydrin solutions. Flash column chromatography or Combi Flash chromatography was carried out on SiO 2 (silica gel 60, 230-400 mesh ASTM, Merck). Drying of the organic extracts during the workup of the reactions was performed with MgSO 4 . A racemic Michael adduct sample for chiral HPLC analysis was prepared in the absence of the catalyst by combining (route A): Michael acceptor 2 (9.4 mmol), nitromethane (47.2 mmol) and diethylamine (14.1 mmol) in DCM (20 mL) at room temp.; (route B): nitroalkene 3 (7.7 mmol), Meldrum's acid (11.6 mmol) and diethylamine (1.2 mL) in DCM (20 mL) at room temp.
Representative Procedure for Screening of the Catalyst. Route A: Meldrum's acid derivative 2 (125 mg, 0.58 mmol) and the chosen thiourea catalyst (0.05 mmol) in the appropriate solvent (0.5 mL) were loaded in a capped vial. After 5 min, nitromethane (1.6 mmol) was added, and stirring was maintained at room temp. The conversion was determined by 1 H NMR spectroscopy of the crude product. Route B: Nitroalkene 3 (100 mg, 0.77 mmol) and the chosen thiourea catalyst (0.07 mmol) in the appropriate solvent (0.5 mL) were loaded in a capped vial. After 5 min, Meldrum's acid (1.44 mmol) was added and stirring was maintained at the specified temperature. The conversion was determined by 1 H NMR spectroscopy of the crude product. The multiplicities are abbreviated as s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet); the prefix br. is applied when the signal in question is broadened. For the 13 C NMR spectra, the solvent peaks of CDCl 3 (δ = 77.0 ppm) and [D 4 ]methanol (δ = 49.0 ppm) were used as the internal standard. High-resolution mass spectrometric data were obtained at the
Instrumentation
Helsinki University of Technology Mass Spectrometry Facility with Waters LCT Premierspectrometer. IR spectra were recorded with a Perkin-Elmer instrument, the data are represented as wavenumbers in cm -1 . Optical rotations were obtained with a Perkin-Elmer 343 polarimeter (λ = 589 nm) with a 1 dm path length. Chiral HPLC analysis was performed by using a Waters 501 pump, a Waters UV 2487 dual lambda-absorbance detector and a Chiralcel OD column (0.46 ϫ 25 cm). Elemental analyses were performed with a PerkinElmer (PE) 2400 Series II CHNS/O Analyzer. Melting points were determined in open capillary tubes and are uncorrected.
(+)-(3S)-3-(Aminomethyl)-5-methylhexanoic Acid Hydrochloride (1·HCl):
[4e] Diacid 5 (4.77 g, 23.5 mmol) was dissolved in 6 n HCl (35 mL) and refluxed for 28 h. Then, the brown aqueous solution was extracted with DCM. Heating of the aqueous layer with activated charcoal followed by filtration through Celite and concentration of the aqueous layer to dryness under reduced pressure furnished a residue, which was dried at 50°C for 48 h. After this period, 1·HCl (Pregabalin hydrochloride) was obtained (4. A crop of Pregabalin hydrochloride was converted into the free amino acid by addition of 1 m NaOH solution until the pH = 7.5. After evaporation of water, a white solid compound was obtained. Crystallization of this material from 30 % 2-propanolinwaterafforded1(Pregabalin)asawhitecrystallinesolid. [3] [α] D 20 = +8.2 (c = 1.07, H 2 O) {ref. [3] [α] D 20 = +10.1 (c = 1.1, H 2 O)}. M.p. 174-175°C (ref. [3] 175-176°C). For the purposes of the ee determination after crystallization, the amine was Boc-protected and the acid converted into the N-methyl amide. [20] N-Boc Protection of Free Amino Acid 1: NaHCO 3 (791 mg, 9.42 mmol) and Boc 2 O (822 mg, 3.77 mmol) were added consecutively at 0°C to a solution of the free amino acid 1 (crystallized from 30 % 2-propanol in water, 500 mg, 3.14 mmol) in a 1:1 mixture of THF/H 2 O (20 mL). After 30 min, the white suspension was stirred at room temp. overnight. Then, the mixture was extracted with Et 2 O. The aqueous layer was acidified to pH = 4 by addition of 5 % citric acid solution at 0°C and extracted with DCM. The extracts were dried and concentrated to give the corresponding Boc-amino acid (512 mg, 63 %) as a white solid, which was used without further purification.
N-Methyl Amidation of Protected Amino Acid 1: N-Methylmorph-
oline (146 μL, 1.15 mmol) and isobutyl chloroformate (150 μL, 1.15 mmol) were successively added to a solution of the Boc-protected amino acid 1 (300 mg, 1.15 mmol) in THF (3 mL) at -20°C. After an activation period of 5 min, 40 % aqueous methylamine (4.60 mmol) in THF (2 mL) was added, and the resulting solution was stirred at -20°C for 1 h prior the addition of 5 % NaHCO 3 (5 mL). After 30 min of stirring at room temp., the mixture was extracted with DCM. The organic layers were washed with 5 % NaHCO 3 , dried and concentrated to provide a pale yellow oil, which after purification by column chromatography (50 % EtOAc in hexane) yielded the desired compound (259 mg, 83 %) as a white solid. The enantiomeric ratio was determined by HPLC: Chiralcel OD column (0.46 cm ϫ 25 cm), hexane/2-propanol (98:2), flow 0.2 mL/min, detector λ = 215 nm, retention time 1: 77.33 min, % area: 10.2, retention time 2: 81.84 min, % area: 89.8.
2,2-Dimethyl-5-(3Ј-methylbutylidene)-1,3-dioxane-4,6-dione (2):
A mixture of Meldrum's acid (4.40 g, 30.5 mmol) and freshly distilled isovaleraldehyde (3 mL, 27.9 mmol) in water (60 mL) was stirred in a closed vessel at 75°C for 2 h. After cooling to room temp., the crude mixture was made alkaline with a saturated aqueous solution of sodium carbonate and extracted with diethyl ether. The extracts were dried, filtered and concentrated under reduced pressure to give pure 2 (3.10 g, 53 %) as a pale yellow oil, which was used without further purification. R f = 0. 
Dehydration of 3-Methyl-1-(nitromethyl)butanol:
Trifluoroacetic anhydride (59.5 mL, 0.42 mol) and then dropwise TEA (117 mL, 0.84 mol) were added successively to a solution of 3-methyl-1-(nitromethyl)butanol (58 g, 0.40 mol) in DCM (500 mL) cooled to 0°C. The reaction mixture was warmed to room temp. After stirring overnight, DCM (200 mL) was added. The organic phase was washed several times with water, saturated aqueous ammonium chloride solution and brine, then dried. After filtration and evaporation in vacuo, distillation under aspirator vacuum at 115°C afforded compound 3 (36 g, 70 %), only detected as the (E) isomer. 5-[(1ЈS)-3Ј-methyl-1Ј-(nitromethyl)butyl]-1,3-dioxane-4,6-dione (4) . 1st Batch: To a solution of nitroalkene 3 (4.33 g, 33.6 mmol) in DCM (35 mL) was added organocatalyst 13 (2.1 g, 3.36 mmol). After 5 min, Meldrum's acid (4.84 g, 33.6 mmol) was added, and the solution was stirred at room temp. for 23 h. Then, the crude mixture was poured into 5 % aqueous citric acid solution, and the aqueous layer was extracted with DCM. After washing with brine, the extracts were dried, filtered and the solvents evaporated in vacuo to give a yellow oil. This was purified by column chromatography (50 % to 80 % EtOAc in hexane) providing compound 4 [7. 
2,2-Dimethyl-

2-[(1ЈS)-1Ј-(Aminomethyl)-3Ј-methylbutyl]propandioic Acid (5):
Nitro compound 4 (9.04 g, 32.9 mmol) in AcOH (200 mL) was added to a solution of Raney-Ni in water (4.5 g of the commercially available wet suspension). The resulting black suspension was stirred at room temp. under H 2 at atmospheric pressure for 22 h (reaction monitored by 1 H NMR spectroscopy). The crude mixture was filtered through a pad of Celite, and the green filtrate was diluted with water and adjusted to pH values between 2 and 3. The aqueous layer was extracted with DCM four times, and the extracts were dried, filtered and the solvents evaporated under vacuum to give diacid 5 (4.99 g, 75 %) as a yellowish oil used in the next step without further purification. 9-Amino-9-deoxyepiquinidine (7): [21] Diisopropyl azodicarboxylate (DIAD, 7.33 mL, 37.0 mmol) was added to a solution of the quinidine alkaloid (10 g, 30.8 mmol) and triphenylphosphane (9.7 g, 37.0 mmol) in absolute THF (100 mL) at 0°C all at once. After 5 min, a solution of diphenylphosphoryl azide (DPPA, 8.02 mL, 37 mmol) in dry THF (50 mL) was added dropwise at 0°C. The mixture was warmed to room temp. After being stirred overnight, the solution was heated at 50°C for 2 h. Then, triphenylphosphane was added, and the heating was maintained until the gas evolution had ceased. The solution was cooled to room temp., and water (10 mL) was added. After stirring for 4 h, the solvents were removed, and the residue was dissolved in DCM and 2 m HCl (1:1, 200 mL). The aqueous phase was extracted with DCM (3 ϫ 100 mL). Then, the aqueous phase was made alkaline with a saturated aqueous solution of Na 2 CO 3 and extracted with DCM. Concentration of the dried extracts afforded a residue, which was purified by column chromatography to yield the desired product 7 (5. 
Preparation of Thiourea Catalysts 8-15:
A solution of the corresponding isothiocyanate in THF (0.8 m) was added to a stirred solution of the free amine 7 in THF (0.8 m) at room temp. After reaction overnight, the solvent was removed under reduced pressure and the residue submitted to flash column chromatography.
N-[3,5-Bis(trifluoromethyl)phenyl]-NЈ-[(9R)-6Ј-methoxycinchonan-9-yl]thiourea (8):
[6b] Thiourea 8 (570 mg, 55 %) was obtained as an amorphous solid after purification by column chromatography from amine 7 (568 mg, 1.75 mmol) and commercially available 3,5-bis(trifluoromethyl)phenyl isothiocyanate (18) 
N-tert-Butyl-NЈ-[(9R)-6Ј-methoxycinchonan-9-yl]thiourea (9):
Thiourea 9 (578 mg, 70 %) was obtained after flash column chromatography as an amorphous solid from amine 7 (626 mg, 1.94 mmol) and tert-butyl isothiocyanate (20) [24] Commercially available 1-bromo-3,5-dimethylbenzene (7 g, 37.8 mmol) in dry Et 2 O (5 mL) was added dropwise to a stirred suspension of granular lithium (0.66 g, 95.1 mmol) in dry Et 2 O (15 mL) at -10°C. The mixture reacted exothermically and refluxed spontaneously. After the addition was complete, the mixture was stirred at room temp. for 10 min. Then, commercially available methyl 3,5-dimethylbenzoate (2.48 g, 15.1 mmol) in dry Et 2 O (10 mL) was added dropwise, and the mixture was stirred at room temp. overnight. Then the excess of lithium and the lithium salts were removed by filtration, and the filtrate was poured into a saturated aqueous solution of ammonium chloride. After Et 2 O extraction of the aqueous layer, the organic phases were dried, filtered and concentrated to yield alcohol 28 as a white solid (4.746 g, 91 %). Crystallization from hexane gave needle-like crystals. M.p. 155-156°C (ref. [24] 158°C). R f = 0. 3 g, 3 .78 mmol) in nitromethane (10 mL). The mixture was stirred at 60°C for 3 h. Then, the crude mixture was poured into a saturated solution of Na 2 CO 3 and extracted with Et 2 O. The extracts were dried, filtered and concentrated to give a pale yellow oil. This was purified by flash column chromatography ( 
Tris(3,5-dimethylphenyl)methanol (28):
